ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats

Oliver A. Garden, Linda Kidd, Angela M. Mexas, Yu Mei Chang, Unity Jeffery, Shauna L. Blois, Jonathan E. Fogle, Amy L. MacNeill, George Lubas, Adam Birkenheuer, Simona Buoncompagni, Julien R.S. Dandrieux, Antonio Di Loria, Claire L. Fellman, Barbara Glanemann, Robert Goggs, Jennifer L Granick, Dana N. LeVine, Claire R. Sharp, Saralyn Smith-CarrJames W. Swann, Balazs Szladovits

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Immune-mediated hemolytic anemia (IMHA) is an important cause of morbidity and mortality in dogs. IMHA also occurs in cats, although less commonly. IMHA is considered secondary when it can be attributed to an underlying disease, and as primary (idiopathic) if no cause is found. Eliminating diseases that cause IMHA may attenuate or stop immune-mediated erythrocyte destruction, and adverse consequences of long-term immunosuppressive treatment can be avoided. Infections, cancer, drugs, vaccines, and inflammatory processes may be underlying causes of IMHA. Evidence for these comorbidities has not been systematically evaluated, rendering evidence-based decisions difficult. We identified and extracted data from studies published in the veterinary literature and developed a novel tool for evaluation of evidence quality, using it to assess study design, diagnostic criteria for IMHA, comorbidities, and causality. Succinct evidence summary statements were written, along with screening recommendations. Statements were refined by conducting 3 iterations of Delphi review with panel and task force members. Commentary was solicited from several professional bodies to maximize clinical applicability before the recommendations were submitted. The resulting document is intended to provide clinical guidelines for diagnosis of, and underlying disease screening for, IMHA in dogs and cats. These should be implemented with consideration of animal, owner, and geographical factors.

Original languageEnglish (US)
Pages (from-to)313-334
Number of pages22
JournalJournal of veterinary internal medicine
Volume33
Issue number2
DOIs
StatePublished - Mar 1 2019

Fingerprint

hemolytic anemia
Hemolytic Anemia
Cats
Dogs
cats
dogs
Immune System Diseases
Comorbidity
screening
immunosuppressive agents
Cancer Vaccines
rendering
Advisory Committees
Immunosuppressive Agents
Causality
morbidity
erythrocytes
Erythrocytes
experimental design
Guidelines

Keywords

  • Delphi survey
  • comorbidity
  • direct antiglobulin test
  • erythrocyte
  • evidence
  • flow cytometry
  • hemolysis
  • iceberg model
  • spherocyte
  • veterinary and comparative clinical immunology society

Cite this

Garden, O. A., Kidd, L., Mexas, A. M., Chang, Y. M., Jeffery, U., Blois, S. L., ... Szladovits, B. (2019). ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats. Journal of veterinary internal medicine, 33(2), 313-334. https://doi.org/10.1111/jvim.15441

ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats. / Garden, Oliver A.; Kidd, Linda; Mexas, Angela M.; Chang, Yu Mei; Jeffery, Unity; Blois, Shauna L.; Fogle, Jonathan E.; MacNeill, Amy L.; Lubas, George; Birkenheuer, Adam; Buoncompagni, Simona; Dandrieux, Julien R.S.; Di Loria, Antonio; Fellman, Claire L.; Glanemann, Barbara; Goggs, Robert; Granick, Jennifer L; LeVine, Dana N.; Sharp, Claire R.; Smith-Carr, Saralyn; Swann, James W.; Szladovits, Balazs.

In: Journal of veterinary internal medicine, Vol. 33, No. 2, 01.03.2019, p. 313-334.

Research output: Contribution to journalReview article

Garden, OA, Kidd, L, Mexas, AM, Chang, YM, Jeffery, U, Blois, SL, Fogle, JE, MacNeill, AL, Lubas, G, Birkenheuer, A, Buoncompagni, S, Dandrieux, JRS, Di Loria, A, Fellman, CL, Glanemann, B, Goggs, R, Granick, JL, LeVine, DN, Sharp, CR, Smith-Carr, S, Swann, JW & Szladovits, B 2019, 'ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats', Journal of veterinary internal medicine, vol. 33, no. 2, pp. 313-334. https://doi.org/10.1111/jvim.15441
Garden, Oliver A. ; Kidd, Linda ; Mexas, Angela M. ; Chang, Yu Mei ; Jeffery, Unity ; Blois, Shauna L. ; Fogle, Jonathan E. ; MacNeill, Amy L. ; Lubas, George ; Birkenheuer, Adam ; Buoncompagni, Simona ; Dandrieux, Julien R.S. ; Di Loria, Antonio ; Fellman, Claire L. ; Glanemann, Barbara ; Goggs, Robert ; Granick, Jennifer L ; LeVine, Dana N. ; Sharp, Claire R. ; Smith-Carr, Saralyn ; Swann, James W. ; Szladovits, Balazs. / ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats. In: Journal of veterinary internal medicine. 2019 ; Vol. 33, No. 2. pp. 313-334.
@article{bbf8313894cb47d8a039b94088895169,
title = "ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats",
abstract = "Immune-mediated hemolytic anemia (IMHA) is an important cause of morbidity and mortality in dogs. IMHA also occurs in cats, although less commonly. IMHA is considered secondary when it can be attributed to an underlying disease, and as primary (idiopathic) if no cause is found. Eliminating diseases that cause IMHA may attenuate or stop immune-mediated erythrocyte destruction, and adverse consequences of long-term immunosuppressive treatment can be avoided. Infections, cancer, drugs, vaccines, and inflammatory processes may be underlying causes of IMHA. Evidence for these comorbidities has not been systematically evaluated, rendering evidence-based decisions difficult. We identified and extracted data from studies published in the veterinary literature and developed a novel tool for evaluation of evidence quality, using it to assess study design, diagnostic criteria for IMHA, comorbidities, and causality. Succinct evidence summary statements were written, along with screening recommendations. Statements were refined by conducting 3 iterations of Delphi review with panel and task force members. Commentary was solicited from several professional bodies to maximize clinical applicability before the recommendations were submitted. The resulting document is intended to provide clinical guidelines for diagnosis of, and underlying disease screening for, IMHA in dogs and cats. These should be implemented with consideration of animal, owner, and geographical factors.",
keywords = "Delphi survey, comorbidity, direct antiglobulin test, erythrocyte, evidence, flow cytometry, hemolysis, iceberg model, spherocyte, veterinary and comparative clinical immunology society",
author = "Garden, {Oliver A.} and Linda Kidd and Mexas, {Angela M.} and Chang, {Yu Mei} and Unity Jeffery and Blois, {Shauna L.} and Fogle, {Jonathan E.} and MacNeill, {Amy L.} and George Lubas and Adam Birkenheuer and Simona Buoncompagni and Dandrieux, {Julien R.S.} and {Di Loria}, Antonio and Fellman, {Claire L.} and Barbara Glanemann and Robert Goggs and Granick, {Jennifer L} and LeVine, {Dana N.} and Sharp, {Claire R.} and Saralyn Smith-Carr and Swann, {James W.} and Balazs Szladovits",
year = "2019",
month = "3",
day = "1",
doi = "10.1111/jvim.15441",
language = "English (US)",
volume = "33",
pages = "313--334",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats

AU - Garden, Oliver A.

AU - Kidd, Linda

AU - Mexas, Angela M.

AU - Chang, Yu Mei

AU - Jeffery, Unity

AU - Blois, Shauna L.

AU - Fogle, Jonathan E.

AU - MacNeill, Amy L.

AU - Lubas, George

AU - Birkenheuer, Adam

AU - Buoncompagni, Simona

AU - Dandrieux, Julien R.S.

AU - Di Loria, Antonio

AU - Fellman, Claire L.

AU - Glanemann, Barbara

AU - Goggs, Robert

AU - Granick, Jennifer L

AU - LeVine, Dana N.

AU - Sharp, Claire R.

AU - Smith-Carr, Saralyn

AU - Swann, James W.

AU - Szladovits, Balazs

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Immune-mediated hemolytic anemia (IMHA) is an important cause of morbidity and mortality in dogs. IMHA also occurs in cats, although less commonly. IMHA is considered secondary when it can be attributed to an underlying disease, and as primary (idiopathic) if no cause is found. Eliminating diseases that cause IMHA may attenuate or stop immune-mediated erythrocyte destruction, and adverse consequences of long-term immunosuppressive treatment can be avoided. Infections, cancer, drugs, vaccines, and inflammatory processes may be underlying causes of IMHA. Evidence for these comorbidities has not been systematically evaluated, rendering evidence-based decisions difficult. We identified and extracted data from studies published in the veterinary literature and developed a novel tool for evaluation of evidence quality, using it to assess study design, diagnostic criteria for IMHA, comorbidities, and causality. Succinct evidence summary statements were written, along with screening recommendations. Statements were refined by conducting 3 iterations of Delphi review with panel and task force members. Commentary was solicited from several professional bodies to maximize clinical applicability before the recommendations were submitted. The resulting document is intended to provide clinical guidelines for diagnosis of, and underlying disease screening for, IMHA in dogs and cats. These should be implemented with consideration of animal, owner, and geographical factors.

AB - Immune-mediated hemolytic anemia (IMHA) is an important cause of morbidity and mortality in dogs. IMHA also occurs in cats, although less commonly. IMHA is considered secondary when it can be attributed to an underlying disease, and as primary (idiopathic) if no cause is found. Eliminating diseases that cause IMHA may attenuate or stop immune-mediated erythrocyte destruction, and adverse consequences of long-term immunosuppressive treatment can be avoided. Infections, cancer, drugs, vaccines, and inflammatory processes may be underlying causes of IMHA. Evidence for these comorbidities has not been systematically evaluated, rendering evidence-based decisions difficult. We identified and extracted data from studies published in the veterinary literature and developed a novel tool for evaluation of evidence quality, using it to assess study design, diagnostic criteria for IMHA, comorbidities, and causality. Succinct evidence summary statements were written, along with screening recommendations. Statements were refined by conducting 3 iterations of Delphi review with panel and task force members. Commentary was solicited from several professional bodies to maximize clinical applicability before the recommendations were submitted. The resulting document is intended to provide clinical guidelines for diagnosis of, and underlying disease screening for, IMHA in dogs and cats. These should be implemented with consideration of animal, owner, and geographical factors.

KW - Delphi survey

KW - comorbidity

KW - direct antiglobulin test

KW - erythrocyte

KW - evidence

KW - flow cytometry

KW - hemolysis

KW - iceberg model

KW - spherocyte

KW - veterinary and comparative clinical immunology society

UR - http://www.scopus.com/inward/record.url?scp=85062351007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062351007&partnerID=8YFLogxK

U2 - 10.1111/jvim.15441

DO - 10.1111/jvim.15441

M3 - Review article

C2 - 30806491

AN - SCOPUS:85062351007

VL - 33

SP - 313

EP - 334

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 2

ER -